You are here

Press Release Archive

- Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility

(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of a Phase 3 randomized,
open-label, two-arm study (B1931008) evaluating the safety and efficacy
of the investigational compound inotuzumab ozogamicin in patients with
relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who
are not candidates for intensive high-dose chemotherapy. In this study,
inotuzumab ozogamicin was administered on a once-a-month schedule in
combination withmore...

- Pfizer Announces 11 Abstracts for Tofacitinib to Be Presented at the European League Against Rheumatism (EULAR) 2013 Annual Meeting

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that 11 abstracts for
tofacitinib will be presented at the European League Against Rheumatism
(EULAR) 2013 Annual Meeting being held June 12-15 in Madrid, Spain. The
brand name for tofacitinib is XELJANZ® (ZEL’ JANS’).

Highlights include:

Comparison of monotherapy vs. combination therapy with tofacitinib

A meta-analysis of four Phase 3 trials (ORAL Sync, Standard, Scanmore...

- Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen
to a webcast of a presentation by Mikael Dolsten, President, Worldwide
Research and Development, at the Morgan Stanley 2013 R&D Seminar:
Reigniting Pharma on Friday, May 10, 2013 at 11:00 a.m. Eastern Daylight

To view and listen to the webcast, visit our web site at
and click on the “Morgan Stanley 2013 R&D Seminar: Reigniting Pharmamore...

- Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from this subanalysis showed that the reductions in stroke or systemic embolism, number of  major bleeding events and mortality demonstrated with Eliquis® (apixaban) compared to warfarin in the ARISTOTLE trial were consistent acrossmore...

- Facing Off Against Counterfeit Online Pharmacies: Pfizer Launches New Purchasing Website To Help Alleviate the Guesswork Around Buying Legitimate Viagra® (sildenafil citrate) Online

(BUSINESS WIRE)--To meet the needs of consumers who are increasingly going online to purchase prescription medications, Pfizer today launched Viagra® home delivery, a new prescription-fulfillment website for Viagra® (sildenafil citrate) tablets, Pfizer’s most counterfeited medicine. The site, which is powered by CVS/pharmacy and accessible through, offers men with erectile dysfunction (ED) an opportunity to purchase Viagra online (with a validmore...

- Pfizer Reports First-Quarter 2013 Results

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter
2013 and updated certain components of its 2013 financial guidance to
reflect the impact of recent changes in foreign exchange rates and the
initial public offering (IPO) of a 19.8% ownership interest in Zoetis(1)
completed on February 6, 2013, among other factors. Pfizer continues to
consolidate Zoetis(1), as Pfizer retains an 80.2% ownership
interest. The earningsmore...

- Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes

Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada (“Merck”), and Pfizer Inc. (NYSE:PFE) today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer’s ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes. Ertugliflozin is Phase III ready, with trials expected to begin later inmore...

- Pfizer Presents Phase 3 Safety And Immunogenicity Data On Prevenar 13 In Adults Aged 18 To 49 Years

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age. The study met all primary and secondary objectives and provides the clinical foundation for the Company’s regulatory submission in the European Union (EU) and planned regulatory submissions in the Unitedmore...

- Pfizer Receives CHMP Negative Opinion Regarding Marketing Authorization In Europe For Rheumatoid Arthritis Treatment XELJANZ® (tofacitinib citrate)

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for XELJANZ® (tofacitinib citrate) for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA). The CHMP is of the opinion that XELJANZ does not demonstrate a favorable risk:benefit profile at this time and recommended against marketingmore...

- Pfizer Hosts Annual Meeting Of Shareholders

(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 24-cent
second-quarter 2013 dividend on the company’s common stock, payable June
4, 2013, to shareholders of record at the close of business on May 10,
2013. The second-quarter 2013 cash dividend will be the 298th
consecutive quarterly dividend paid by Pfizer.

“Through dividends and share repurchases, we returned approximately $15
billion to our shareholders in 2012,” said Ian Readmore...

- Top-Line Data Show Celecoxib Met Primary Objective In Clinical Trial To Evaluate The Effects On Blood Pressure In Pediatric Patients With Juvenile Idiopathic Arthritis

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced top-line results for a Phase 4
clinical trial in which the primary objective was to measure blood
pressure (hypertension) among pediatric patients with Juvenile
Idiopathic Arthritis (JIA; also known as Juvenile Rheumatoid Arthritis
or JRA) taking celecoxib (Celebrex) capsules or naproxen.

The results demonstrated there was virtually no difference in changes to
systolic blood pressure, the primarymore...

- Pfizer Invites Public To Listen To Webcast Of April 25 Annual Meeting Of Shareholders

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a
webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern
Daylight Time) on Thursday, April 25. To access the webcast, visit our
website at
and click on the “Annual Meeting of Shareholders Webcast” link.

Information on accessing and pre-registering for the live audio webcast
will be available at

- Millions of US Teens May Be Missing Out on Annual Checkups, and the Opportunity to be Screened for Potential Health Risks

Approximately one-third of teens may be missing annual checkups according to data from the US Department of Health and Human Services1 and the US Census.2 Teens often encounter social, emotional, and physical issues that may include eating disorders and obesity, substance abuse, and sexually transmitted infections.[3] While experts agree that teens should get annual medical checkups to be screened for health risks and discuss important health-related matters,[4],3 perceptions exist thatmore...

- Pfizer’s Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer

(BUSINESS WIRE)--Pfizer Inc. announced today its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has received Breakthrough Therapy designation by the United States Food and Drug Administration (FDA) for the potential treatment of patients with breast cancer.Enacted as part of the 2012 FDA Safety and Innovation Act (FDASIA), Breakthrough Therapy designation is intended to expedite the development and review of a potential new medicinemore...

- Pfizer Launches Third Integrated Annual Review

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the launch of its third integrated annual review ( which summarizes the company’s 2012 financial, environmental and social responsibility performance. Pfizer Chairman and Chief Executive Officer Ian C. Read said in his annual letter to stakeholders that the company had a pivotal year for pipeline development, launching five new therapies and making significant progress

- Advil® Launches Advil® Relief in Action Campaign Celebrating Active Volunteers Who Don’t Let Pain Hold Them Back

(BUSINESS WIRE)--Pfizer Consumer Healthcare (NYSE: PFE), makers of Advil®, is kicking off its Advil® Relief in Action campaign today that honors volunteers who don’t let pain get in the way of providing relief to others in need. Advil® Relief in Action celebrates the efforts of these tireless everyday heroes, as well as supports and contributes to the efforts of Habitat for Humanity and Wounded Warrior Project® (WWP), whose volunteers exemplify Relief in Action

- CHOP Collaborates With Pfizer’s Centers For Therapeutic Innovation To Speed Pediatric Research & Development

The Children’s Hospital of Philadelphia (CHOP) and Pfizer Inc. are joining forces with the goal of translating biomedical discoveries into novel treatments.  CHOP is announcing its participation in the Centers for Therapeutic Innovation (CTI) network, a novel collaboration model built by Pfizer that brings academic researchers together with Pfizer scientists to expedite the pace of innovation. Children’s Hospital is only the second pediatric center to join the CTI network, which has

- Pfizer’s BOSULIF® (bosutinib) Receives Conditional Marketing Authorization From The European Commission

(BUSINESS WIRE)--Pfizer Inc. announced today that the European Commission (EC) has granted conditional marketing authorization for BOSULIF® (bosutinib) in the European Union (EU) for the treatment of adult patients with chronic phase (CP), accelerated phase (AP) and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and

- Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, April 30, 2013. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2013 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at

- Over 50? Of Course You’ve Still Got It, and the Y and Pfizer are Launching 50 MOVING FORWARD to Help You Keep It

(BUSINESS WIRE)--Forget “50 is the new 40” or even “the new 30,” age 50 is about moving forward. That’s why YMCA of the USA (Y-USA) and Pfizer Inc launched 50 MOVING FORWARD, a healthy living plan designed to motivate adults 50 years and older with fresh ideas about behaviors that experts say are crucial to healthy aging: physical activity; preventive measures like screenings and vaccinations; healthy eating; and social interaction. Those who want


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.